 "Centre clears Mumbai's Haffkine to make Covaxin vaccine as cases rise")
In a major step to ramp up vaccine production amid the Covid-19 second wave, the Centre has approved production of Corona vaccines from the Maharashtra government-owned Haffkine Institute in Mumbai.
Since the past month, Chief Minister Uddhav Thackeray had repeatedly requested Prime Minister Narendra Modi to allow production of vaccines in the renowned institution in central Mumbai.
The central approval came late on Thursday night green-flagging the 122-year-old Haffkine Institute, Parel, to produce the Bharat Biotech's Covaxin for one-year under a technology transfer agreement.
Shortly after the announcement, Thackeray thanked the PM for the formal nod, sent by the Department of Science & Technology Secretary to state Chief Secretary Sitaram Kunte of the approval for a period of 12 months.
The Haffkine Institute has the capacity to produce 22-crore doses annually, which would immensely help the ongoing Vaccination drive in the country with complaints of vaccine shortages coming up from several states including Maharashtra.
--IANS
qn/sdr/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app